Evolus boasts early resubmission of FDA-rejected Botox alternative

By Flora Southey contact

- Last updated on GMT

(Image: Getty/DenizA)
(Image: Getty/DenizA)

Related tags: Allergan, Fda, Botox

Three months after the US FDA vetoed Evolus’ Botox alternative, the firm has announced its resubmission of DWP-450 for approval.

Evolus’ lead candidate, DWP-450 (prabotulinumtoxinA), is a 900 kDa purified botulinum toxin type A complex. As an alternative to Allergan’s onabotulinumtoxinA (Botox), the product is designed to temporarily improve the appearance of moderate to severe frown lines, also known as glabellar lines.

The resubmission comes less than 90 days after Evolus announced receipt of a complete response letter​ (CRL) from the US Food and Drug Administration (FDA).

The CRL flagged chemistry, manufacturing, and controls (CMC) processes, according to Evolus: “No deficiencies were related to clinical, non-clinical or safety matters.”

“We believe this [most recent] submission gives us a line of sight to the anticipated approval and subsequent commercialisation of DWP-450,” ​said CEO David Moatazedi in a statement​.

“We look forward to receiving notice next month of the FDA’s acceptance of our resubmission and the assignment of a new FDA action date,” ​he added. The firm expects to launch DWP-450 in spring 2019.

Evolus has overcome significant regulatory hurdles to get to the point of resubmission. In addition to the CRL, the firm’s contract manufacturing organisation (CMO), Daewoong Pharmaceutical, received a Form 483 with ten observations​ for its Hwaseong-si facility in South Korea last year. The CMO had specifically built the site to make DWP-450.

However, in May 2018, Evolus announced the FDA had validated the facility​ in an establishment inspection report to Daewoong.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us


View more